Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
